Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
Van Cutsem, E Bajetta, E Valle, Juan W Köhne, C H Hecht, J R Moore, M Germond, C Berg, W Chen, B L Jalava, T
Van Cutsem, E
Bajetta, E
Valle, Juan W
Köhne, C H
Hecht, J R
Moore, M
Germond, C
Berg, W
Chen, B L
Jalava, T
Citations
Altmetric:
Abstract
Treatment options for patients with previously treated metastatic colorectal cancer (mCRC) are limited, and treatments with differing mechanisms of action are needed. PTK787/ZK 222584 (PTK/ZK) is a novel oral angiogenesis inhibitor with therapeutic potential for the treatment of solid tumors.
Description
Date
2011-05-20
Publisher
Collections
Keywords
Type
Article
Citation
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. 2011, 29 (15):2004-10 J Clin Oncol